Alphatec Holdings, Inc. (NASDAQ:ATEC) Given Consensus Recommendation of “Buy” by Analysts

Alphatec Holdings, Inc. (NASDAQ:ATEC) has been assigned an average rating of “Buy” from the six ratings firms that are presently covering the stock, MarketBeat reports. Six equities research analysts have rated the stock with a buy rating. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $18.50.

A number of research analysts have recently issued reports on the company. Canaccord Genuity Group reiterated a “buy” rating and issued a $20.00 price target on shares of Alphatec in a report on Friday, August 1st. Wall Street Zen lowered Alphatec from a “buy” rating to a “hold” rating in a research note on Saturday, August 30th. Lake Street Capital upgraded shares of Alphatec to a “buy” rating and set a $18.00 target price for the company in a report on Monday, June 16th. Finally, Barclays restated an “overweight” rating and issued a $22.00 price target (up from $21.00) on shares of Alphatec in a report on Monday, August 4th.

Insider Activity at Alphatec

In other news, General Counsel Tyson Eliot Marshall sold 18,092 shares of the firm’s stock in a transaction dated Tuesday, August 5th. The stock was sold at an average price of $14.91, for a total value of $269,751.72. Following the completion of the transaction, the general counsel directly owned 438,331 shares in the company, valued at $6,535,515.21. This trade represents a 3.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Craig E. Hunsaker sold 50,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 5th. The stock was sold at an average price of $15.00, for a total transaction of $750,000.00. Following the transaction, the executive vice president directly owned 1,400,018 shares of the company’s stock, valued at $21,000,270. This represents a 3.45% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 510,247 shares of company stock valued at $7,627,527. Company insiders own 20.90% of the company’s stock.

Institutional Investors Weigh In On Alphatec

Hedge funds have recently bought and sold shares of the stock. Comerica Bank raised its position in shares of Alphatec by 66.8% in the fourth quarter. Comerica Bank now owns 3,116 shares of the medical technology company’s stock worth $29,000 after acquiring an additional 1,248 shares during the period. Osterweis Capital Management Inc. purchased a new position in shares of Alphatec in the 2nd quarter valued at about $37,000. Larson Financial Group LLC acquired a new position in Alphatec in the 1st quarter worth about $54,000. Nisa Investment Advisors LLC raised its holdings in Alphatec by 22.4% in the 2nd quarter. Nisa Investment Advisors LLC now owns 5,714 shares of the medical technology company’s stock worth $63,000 after purchasing an additional 1,045 shares during the period. Finally, Lazard Asset Management LLC purchased a new position in Alphatec during the fourth quarter worth approximately $76,000. Hedge funds and other institutional investors own 66.35% of the company’s stock.

Alphatec Stock Performance

Shares of Alphatec stock opened at $16.55 on Friday. The company has a quick ratio of 1.77, a current ratio of 2.88 and a debt-to-equity ratio of 23.22. The stock’s fifty day moving average is $13.27 and its two-hundred day moving average is $11.87. Alphatec has a 52 week low of $4.88 and a 52 week high of $16.70. The company has a market capitalization of $2.45 billion, a PE ratio of -14.65 and a beta of 1.02.

Alphatec (NASDAQ:ATEC) last released its quarterly earnings data on Thursday, July 31st. The medical technology company reported $0.02 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.08. Alphatec had a negative net margin of 24.33% and a negative return on equity of 1,657.19%. The company had revenue of $185.54 million during the quarter, compared to analysts’ expectations of $178.85 million. During the same period in the previous year, the company earned ($0.29) EPS. The firm’s quarterly revenue was up 27.5% on a year-over-year basis. Alphatec has set its FY 2025 guidance at EPS. As a group, analysts expect that Alphatec will post -1.08 earnings per share for the current year.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.